GB0206723D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0206723D0
GB0206723D0 GBGB0206723.9A GB0206723A GB0206723D0 GB 0206723 D0 GB0206723 D0 GB 0206723D0 GB 0206723 A GB0206723 A GB 0206723A GB 0206723 D0 GB0206723 D0 GB 0206723D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0206723.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0206723.9A priority Critical patent/GB0206723D0/en
Publication of GB0206723D0 publication Critical patent/GB0206723D0/en
Priority to AU2003219100A priority patent/AU2003219100A1/en
Priority to PCT/EP2003/003171 priority patent/WO2003080616A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
GBGB0206723.9A 2002-03-21 2002-03-21 Novel compounds Ceased GB0206723D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0206723.9A GB0206723D0 (en) 2002-03-21 2002-03-21 Novel compounds
AU2003219100A AU2003219100A1 (en) 2002-03-21 2003-03-20 Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3
PCT/EP2003/003171 WO2003080616A1 (en) 2002-03-21 2003-03-20 Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0206723.9A GB0206723D0 (en) 2002-03-21 2002-03-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB0206723D0 true GB0206723D0 (en) 2002-05-01

Family

ID=9933463

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0206723.9A Ceased GB0206723D0 (en) 2002-03-21 2002-03-21 Novel compounds

Country Status (3)

Country Link
AU (1) AU2003219100A1 (en)
GB (1) GB0206723D0 (en)
WO (1) WO2003080616A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435957B1 (en) * 2001-04-30 2009-06-17 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
EP1551842A1 (en) * 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
SG173409A1 (en) * 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
JP2010523613A (en) * 2007-04-09 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー Non-nucleoside reverse transcriptase inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
PL2701510T3 (en) 2011-04-25 2017-07-31 Usher Iii Initiative Inc Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
CA2889494C (en) * 2012-10-25 2018-12-18 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2017045955A1 (en) * 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
WO2022011091A1 (en) * 2020-07-09 2022-01-13 Usher Iii Initiative, Inc. Treatment of cancer, inflammatory diseases and autoimmune diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348734A1 (en) * 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors

Also Published As

Publication number Publication date
WO2003080616A1 (en) 2003-10-02
AU2003219100A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
GB0202216D0 (en) Novel compounds
GB0205256D0 (en) Novel compounds
GB0202679D0 (en) Novel compounds
GB0206723D0 (en) Novel compounds
GB0207249D0 (en) Novel compounds
GB0207246D0 (en) Novel compounds
GB0226822D0 (en) Novel compounds
GB0203299D0 (en) Novel compounds
GB0200025D0 (en) Novel compounds
GB0204252D0 (en) Novel compounds
GB0203680D0 (en) Novel compounds
GB0206716D0 (en) Novel compounds
GB0203300D0 (en) Novel compounds
GB0207283D0 (en) Novel compounds
GB0207282D0 (en) Novel compounds
GB0203677D0 (en) Novel compounds
GB0207281D0 (en) Novel compounds
GB0203673D0 (en) Novel compounds
GB0207278D0 (en) Novel compounds
GB0203437D0 (en) Novel compounds
GB0207275D0 (en) Novel compounds
GB0203369D0 (en) Novel compounds
GB0200109D0 (en) Novel compounds
GB0203902D0 (en) Novel compounds
GB0203363D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)